FDA panel backs anemia drugs for kidney disease

Oct 18, 2010

(AP) -- Federal health advisers say patients with failing kidneys should continue taking a group of widely used anemia drugs, despite a recent study showing they can increase the risk of stroke.

A panel of experts voted 15-1 to maintain the drugs' approval for patients with chronic who are not yet sick enough to receive dialysis. The FDA is not required to follow the group's advice, though it often does.

The panel is now scheduled to discuss altering recommended doses of the drugs to increase their safety.

The FDA is reviewing the three blood-boosting medications from Amgen Inc. after a study published last year that showed kidney disease patients taking them were twice as likely to experience compared with those taking a dummy treatment.

Explore further: High-dose opioid prescribing continues to climb

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Study finds stroke risk from anemia drug Aranesp

Oct 31, 2009

(AP) -- A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick ...

FDA questions safety of Glaxo kidney cancer drug

Oct 01, 2009

(AP) -- Federal regulators said Thursday an experimental kidney cancer drug from GlaxoSmithKline may cause liver problems, potentially outweighing its ability to slow the disease.

Abbott withdraws diet pill in US, Canada

Oct 08, 2010

(AP) -- Abbott Laboratories said Friday it will withdraw its diet pill Meridia in the U.S. and Canada, almost a year after studies showed the drug increases the risk of heart attack and stroke in patients with a history ...

FDA confirms benefits of Crestor in more patients

Dec 11, 2009

(AP) -- Federal scientists say AstraZeneca's cholesterol pill Crestor lowers the risk of heart attack, death and stroke in patients without a history of heart disease, though some safety concerns remain.

Recommended for you

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

FDA approves weight-loss drug Contrave (Update)

Sep 11, 2014

U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.

User comments : 0